# A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Study · id `cardio:ct-nct01672476` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01672476](<https://clinicaltrials.gov/study/NCT01672476>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01672476

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

## Technical summary

Registry record NCT01672476. Randomized; double masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 293 participants (enrolled count; ClinicalTrials.gov record NCT01672476, source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01672476, source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01672476, source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)
- Completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01672476, source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01672476, source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01672476-2016-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
- Acronym: fimasartan
- Condition: Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): Valsartan
- Intervention (Drug): Fimasartan
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Bucheon St. Mary's Hospital
- Collaborator class: OTHER
- Collaborator: Konyang University Hospital
- Collaborator class: OTHER
- Collaborator: Korea University Anam Hospital
- Collaborator class: OTHER
- Collaborator: National Health Insurance Service Ilsan Hospital
- Collaborator class: OTHER
- Collaborator: Daegu Fatima Hospital
- Collaborator class: OTHER
- Collaborator: Dong-A University
- Collaborator class: OTHER
- Collaborator: Soon Chun Hyang University
- Collaborator class: OTHER
- Collaborator: Asan Medical Center
- Collaborator class: OTHER
- Collaborator: Gangnam Severance Hospital
- Collaborator class: OTHER
- Collaborator: Severance Hospital
- Collaborator class: OTHER
- Collaborator: Ulsan University Hospital
- Collaborator class: OTHER
- Collaborator: Kangbuk Samsung Hospital
- Collaborator class: OTHER
- Collaborator: Sejong General Hospital
- Collaborator class: OTHER
- Collaborator: Ewha Womans University Mokdong Hospital
- Collaborator class: OTHER
- Collaborator: Jeju National University Hospital
- Collaborator class: OTHER
- Collaborator: Hallym University Medical Center
- Collaborator class: OTHER
- Collaborator: Hanyang University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study (`cardio:pubmed-25092393`)

Courtesy of the U.S. National Library of Medicine.

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 15 registry organizations

## Provenance

Content hash: 287d78264f5dcc2d959e217d456adf2b8199887ada0b7b08b6768f396119790e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
